<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03768427</url>
  </required_header>
  <id_info>
    <org_study_id>0653C-439</org_study_id>
    <secondary_id>MK-0653C-439</secondary_id>
    <nct_id>NCT03768427</nct_id>
  </id_info>
  <brief_title>Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)</brief_title>
  <official_title>A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowing Treatment in Chinese Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second
      line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants. The
      primary hypothesis is that MK-0653C 10/10 mg is superior to atorvastatin 20 mg in percent
      change from baseline in LDL-C to 12 weeks after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2019</start_date>
  <completion_date type="Anticipated">February 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C at Week 12 (Cohort A)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C at Week 12 (Cohort B)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with An Adverse Event (AE)</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product. The number of participants in any treatment group with at least one AE was assessed over 12 weeks of treatment with MK-0653C, plus 14 days (2 weeks) of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued From Study Treatment</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>The number of participants who discontinued treatment over the 12-week treatment period was assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>EZ 10 mg/Ator 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 atorvastatin 10 mg tablets administered orally, QD for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EZ 10 mg/Ator 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 atorvastatin 20 mg tablets administered orally, QD for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EZ 10 mg/Ator 10 mg</intervention_name>
    <description>FDC of EZ10 mg/Ator 10mg</description>
    <arm_group_label>EZ 10 mg/Ator 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EZ 10 mg/Ator 20 mg</intervention_name>
    <description>FDC of EZ10 mg/Ator 20mg</description>
    <arm_group_label>EZ 10 mg/Ator 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <other_name>Lipitor^®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for FDC EZ/Ator</intervention_name>
    <description>A single placebo tablet administered orally QD for 84 days</description>
    <arm_group_label>EZ 10 mg/Ator 10 mg</arm_group_label>
    <arm_group_label>EZ 10 mg/Ator 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for atorvastatin</intervention_name>
    <description>Two placebo tablets matching atorvastatin administered orally QD for 84 days</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has hypercholesterolemia diagnosed by investigator according to Chinese Guidelines on
             Prevention and Treatment of Dyslipidemia in Adults (2016 Edition).

          -  Has been stabilized on atorvastatin treatment at 10 mg or 20 mg (or other statins with
             LDL-C lowering efficacy equivalent to atorvastatin) for at least 4 weeks prior to
             Visit 1.

          -  If female, is not pregnant or breastfeeding, and is either not a woman of childbearing
             potential (WOCBP), or is a WOCBP who has used a contraceptive consistent with local
             regulations.

          -  If male, has used a contraceptive consistent with local regulations.

          -  Agrees to maintain a stable diet and stable exercise during the study.

        Exclusion Criteria:

          -  Has uncontrolled hypertriglyceridemia which needs drug intervention or a fasting
             triglyceride (TG) value ≥500 mg/dL (4.52 mmol/L).

          -  Is currently treated with statin at dose of equivalent LDL-C lowering effect &gt;20 mg
             atorvastatin.

          -  Has active liver disease

          -  Has New York Heart Association (NYHA) Class III or IV symptomatic congestive heart
             failure at Visit 1.

          -  Has had uncontrolled cardiac arrhythmias, myocardial infarction, percutaneous coronary
             intervention, coronary artery bypass graft, unstable angina, or stroke within 3 months
             (12 weeks) prior to Visit 1.

          -  Has homozygous familial hypercholesterolemia or has undergone LDL apheresis.

          -  Has endocrine or metabolic disease known to influence serum lipids or lipoproteins
             (i.e., secondary causes of hyperlipidemia, e.g., hyper or hypothyroidism, Cushing's
             syndrome).

          -  Has had a gastrointestinal tract bypass, or other significant intestinal
             malabsorption.

          -  Has a history of cancer within the past 5 years from Visit 1 (except for successfully
             treated dermatological basal cell or squamous cell carcinoma or in situ cervical
             cancer).

          -  Is known to be human immunodeficiency virus (HIV) positive.

          -  Has hypersensitivity or intolerance to ezetimibe, atorvastatin, the
             ezetimibe/atorvastatin combination tablet, or any component of these medications or
             has a condition or situation, which is described as a contraindication in labeling of
             EZETROL or Lipitor or may interfere with participation in the study.

          -  Has disorders of the hematologic, digestive, or central nervous systems including
             cerebrovascular disease and degenerative disease that would limit study evaluation or
             participation.

          -  Has a history of mental instability, drug/alcohol abuse within the past 5 years, or
             major psychiatric illness not adequately controlled and stable on pharmacotherapy.

          -  Has a history of myopathy or rhabdomyolysis with ezetimibe or any statin.

          -  Is a WOCBP who has had a positive urine pregnancy test within 24 hours before the
             first dose of study intervention. If the urine test is positive or cannot be confirmed
             as negative, a serum pregnancy test will be required.

          -  Is currently taking medications that are potent modulators of cytochrome P-450 3A4
             (CYP3A4) including: cyclosporine, systemically administered azole antifungals (e.g.,
             ketoconazole, fluconazole, and itraconazole), macrolide antibiotics (e.g.,
             clarithromycin, and erythromycin), protease inhibitors (e.g., ritonavir, saquinavir,
             and lopinavir), grapefruit or juice of grapefruit (200 ml/day for &gt;3 times per week)

          -  Is taking any cyclical hormones (e.g., cyclical oral contraceptives, cyclical hormone
             replacement), including the combination of ethinyl estradiol and norethisterone, or
             non-cyclical hormones, including non-cyclical hormone replacement therapy (HRT) or any
             estrogen antagonist/agonist within 8 weeks.

          -  Note: If participant has been treated with a stable regimen of non-cyclical HRT for &gt;
             8 weeks and agree to continue this regimen for the duration of the trial, concomitant
             therapy is acceptable.

          -  Is receiving treatment with systemic corticosteroids (intravenous, intramuscular and
             oral steroids).

          -  Is treated with psyllium, other fiber-based laxatives, phytosterol margarine, and
             herbal medicine and/or over the counter (OTC) therapies that are known to affect serum
             lipids.

          -  Note: If participant has been treated with a stable regimen for &gt; 8 weeks and agrees
             to continue this regimen for the duration of the trial, concomitant therapy is
             acceptable.

          -  Is treated with an anti-obesity drug (e.g. mazindol) within 12 weeks prior to Visit 1.

          -  Is treated with warfarin or warfarin-like anticoagulants and has not been on a stable
             dose with a stable International Normalized Ratio (INR) for at least 6 weeks.

        weeks.

          -  Has taken lipid-lowering agents (except probucol) including, Cholestin, bile acid
             sequestrants, ezetimibe, fibrates or niacin (&gt;200 mg/day), proprotein convertases
             subtilisin/kexin type 9 (PCSK9) inhibitors within 6 weeks prior to Visit 1.

          -  Has taken probucol within 10 weeks prior to Visit 1.

          -  Has been treated with any other investigational drug within 30 days.

          -  Currently follows an excessive weight reduction diet.

          -  Currently engages in a vigorous exercise regimen (e.g., marathon training, body
             building training) or intends to start training during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital. Capital Medical University ( Site 0001)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613651327758</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aero Space center hospital ( Site 0003)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100049</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861059971771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital ( Site 0005)</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+861063138628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing General Hospital ( Site 0037)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613508322668</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital ( Site 0041)</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+869318942924</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital ( Site 0006)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862083851483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital.Sun Yat-sen University ( Site 0007)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862087330939</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 0008)</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510210</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613688872453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daqing Oilfield General Hospital ( Site 0010)</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+864595805301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Harbin Medical University ( Site 0009)</name>
      <address>
        <city>Haerbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86045185552399</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University ( Site 0013)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8673188618087</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Provincial People's Hospital ( Site 0011)</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613974829586</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College ( Site 0025)</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+864722178224</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University ( Site 0045)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602583272084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University ( Site 0020)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862558509670</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Soochow University ( Site 0048)</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+868906201122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University ( Site 0017)</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613805219897</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital ( Site 0040)</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8618952781166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University ( Site 0038)</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86079186312723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ji Lin Province People Hospital ( Site 0016)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86043185595585</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University ( Site 0015)</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86043184995395</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central People s Hospital of Siping ( Site 0046)</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8604343625127</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Liaoning Province-Cardiovascular ( Site 0022)</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8613904027391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University ( Site 0049)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862160267665</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital ( Site 0031)</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602166111103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Union Medicine Centre ( Site 0032)</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+862258987310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>People s Hospital of Lishui City ( Site 0036)</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <zip>323000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8605782780123</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo First Hospital ( Site 0042)</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+8602166111103</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province ( Site 0035)</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86057685199091</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University ( Site 0034)</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+86057755579281</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>December 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

